Scaling Cell & Gene Therapy: The Future of Automation and Collaboration
Andreas Knaack, CEO & President, Invetech, joins Adam Wolf, Alliance for Regenerative Medicine, during Meeting on the Mesa 2025 to discuss automation in the cell and gene therapy sector. He explains how many of the tools used across the industry today were not designed for the scale and economics required for these advanced therapies and highlights the importance of applying lean principles to improve efficiency. Andreas emphasizes the need for new, scalable technologies that can maintain product quality while helping reduce costs and improve patient access. The conversation covers risks, future trends, and the critical role of partnerships in advancing cell and gene therapy.
Invetech works with diagnostics and cell and gene therapy companies in their quest to bring novel IVD devices and life-saving therapies to market from early feasibility through scale manufacturing and lifecycle support. One integrated team, one point of accountability, at every stage.
Copyright © 2026 Invetech Pty Ltd and its affiliates. All rights reserved. INVETECH and the Invetech logo are trademarks of Invetech Pty ltd.
